{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:32Z","timestamp":1794008792091,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11060-026-05635-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:10:59Z","timestamp":1782184259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma"],"prefix":"10.1007","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-9391","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Barbe-Richaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Cebula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Todeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie des Neiges","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyid","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Blouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"5635_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ncl.2018.04.001","volume":"36","author":"JS Barnholtz-Sloan","year":"2018","unstructured":"Barnholtz-Sloan JS, Ostrom QT, Cote D (2018) Epidemiology of Brain Tumors. Neurol Clin 36:395\u2013419. https:\/\/doi.org\/10.1016\/j.ncl.2018.04.001","journal-title":"Neurol Clin"},{"key":"5635_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5635_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C et al (2021) Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 71:381\u2013406. https:\/\/doi.org\/10.3322\/caac.21693","journal-title":"CA Cancer J Clin"},{"key":"5635_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5635_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ et al (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376:1027\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa1611977","journal-title":"N Engl J Med"},{"key":"5635_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190\u2013198. https:\/\/doi.org\/10.3171\/jns.2001.95.2.0190","journal-title":"J Neurosurg"},{"key":"5635_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"5635_CR8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5635_CR9","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729. https:\/\/doi.org\/10.1200\/JCO.2007.12.2440","journal-title":"J Clin Oncol"},{"key":"5635_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377:1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"key":"5635_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588\u2013593. https:\/\/doi.org\/10.1054\/bjoc.2000.1316","journal-title":"Br J Cancer"},{"key":"5635_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F et al (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36. https:\/\/doi.org\/10.1186\/s13014-021-01767-9","journal-title":"Radiat Oncol"},{"key":"5635_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.wneu.2018.04.016","volume":"115","author":"VM Lu","year":"2018","unstructured":"Lu VM, Jue TR, McDonald KL, Rovin RA (2018) The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis. World Neurosurg 115:453\u2013459e3. https:\/\/doi.org\/10.1016\/j.wneu.2018.04.016","journal-title":"World Neurosurg"},{"key":"5635_CR14","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","volume":"25","author":"A Wick","year":"2007","unstructured":"Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357\u20133361. https:\/\/doi.org\/10.1200\/JCO.2007.10.7722","journal-title":"J Clin Oncol"},{"key":"5635_CR15","doi-asserted-by":"publisher","first-page":"106006","DOI":"10.1016\/j.clineuro.2020.106006","volume":"196","author":"A Seyve","year":"2020","unstructured":"Seyve A, Lozano-Sanchez F, Thomas A et al (2020) Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. Clin Neurol Neurosurg 196:106006. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106006","journal-title":"Clin Neurol Neurosurg"},{"key":"5635_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O van Tellingen","year":"2015","unstructured":"van Tellingen O, Yetkin-Arik B, de Gooijer MC et al (2015) Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19:1\u201312. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002","journal-title":"Drug Resist Updat"},{"key":"5635_CR17","doi-asserted-by":"publisher","first-page":"e0152170","DOI":"10.1371\/journal.pone.0152170","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xing D, Zhao M et al (2016) The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review. PLoS ONE 11:e0152170. https:\/\/doi.org\/10.1371\/journal.pone.0152170","journal-title":"PLoS ONE"},{"key":"5635_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, Zhou Z, Huang X et al (2023) Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer 23:544. https:\/\/doi.org\/10.1186\/s12885-023-11043-6","journal-title":"BMC Cancer"},{"key":"5635_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cells14060407","volume":"14","author":"A Nowacka","year":"2025","unstructured":"Nowacka A, \u015aniegocki M, Smuczy\u0144ski W et al (2025) Angiogenesis in Glioblastoma-Treatment Approaches. Cells 14:407. https:\/\/doi.org\/10.3390\/cells14060407","journal-title":"Cells"},{"key":"5635_CR20","doi-asserted-by":"publisher","first-page":"961014","DOI":"10.3389\/fonc.2022.961014","volume":"12","author":"L She","year":"2022","unstructured":"She L, Su L, Liu C (2022) Bevacizumab combined with re-irradiation in recurrent glioblastoma. Front Oncol 12:961014. https:\/\/doi.org\/10.3389\/fonc.2022.961014","journal-title":"Front Oncol"},{"key":"5635_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP et al (2023) NRG Oncology\/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol 41:1285\u20131295. https:\/\/doi.org\/10.1200\/JCO.22.00164","journal-title":"J Clin Oncol"},{"key":"5635_CR22","first-page":"6962","volume":"63","author":"N Shinojima","year":"2003","unstructured":"Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962\u20136970","journal-title":"Cancer Res"},{"key":"5635_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A et al (2013) The Somatic Genomic Landscape of Glioblastoma. Cell 155:462\u2013477. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"key":"5635_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","volume":"98","author":"DM Peereboom","year":"2010","unstructured":"Peereboom DM, Shepard DR, Ahluwalia MS et al (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98:93\u201399. https:\/\/doi.org\/10.1007\/s11060-009-0067-2","journal-title":"J Neurooncol"},{"key":"5635_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","volume":"51","author":"M Westphal","year":"2015","unstructured":"Westphal M, Heese O, Steinbach JP et al (2015) A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 51:522\u2013532. https:\/\/doi.org\/10.1016\/j.ejca.2014.12.019","journal-title":"Eur J Cancer"},{"key":"5635_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman AB, Pugh SL, Wang TJC et al (2023) Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol 25:339\u2013350. https:\/\/doi.org\/10.1093\/neuonc\/noac173","journal-title":"Neuro Oncol"},{"key":"5635_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A et al (2022) Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol 24:1935\u20131949. https:\/\/doi.org\/10.1093\/neuonc\/noac116","journal-title":"Neuro Oncol"},{"key":"5635_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF et al (2023) Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol 25:123\u2013134. https:\/\/doi.org\/10.1093\/neuonc\/noac099","journal-title":"Neuro Oncol"},{"key":"5635_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A et al (2020) Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol 6:1003\u20131010. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"key":"5635_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S et al (2023) Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol 9:112\u2013121. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5370","journal-title":"JAMA Oncol"},{"key":"5635_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/WNF.0000000000000452","volume":"44","author":"L Tan","year":"2021","unstructured":"Tan L, Peng J, Liu P, Wu Q (2021) The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Clin Neuropharmacol 44:216\u2013221. https:\/\/doi.org\/10.1097\/WNF.0000000000000452","journal-title":"Clin Neuropharmacol"},{"key":"5635_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ et al (2024) Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med 390:1290\u20131298. https:\/\/doi.org\/10.1056\/NEJMoa2314390","journal-title":"N Engl J Med"},{"key":"5635_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA et al (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30:1320\u20131329. https:\/\/doi.org\/10.1038\/s41591-024-02893-z","journal-title":"Nat Med"},{"key":"5635_CR34","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R et al (2024) Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine 106:105266. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266","journal-title":"EBioMedicine"},{"key":"5635_CR35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ijrobp.2024.01.013","volume":"119","author":"ATC Chen","year":"2024","unstructured":"Chen ATC, Serante AR, Ayres AS et al (2024) Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma. Int J Radiat Oncol Biol Phys 119:1122\u20131132. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5635_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-024-04643-0","volume":"168","author":"E Tong","year":"2024","unstructured":"Tong E, Horsley P, Wheeler H et al (2024) Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse. J Neurooncol 168:69\u201376. https:\/\/doi.org\/10.1007\/s11060-024-04643-0","journal-title":"J Neurooncol"},{"key":"5635_CR37","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00701-021-04794-3","volume":"163","author":"DP Kulinich","year":"2021","unstructured":"Kulinich DP, Sheppard JP, Nguyen T et al (2021) Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review. Acta Neurochir (Wien) 163:1921\u20131934. https:\/\/doi.org\/10.1007\/s00701-021-04794-3","journal-title":"Acta Neurochir (Wien)"},{"key":"5635_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ctro.2020.03.005","volume":"22","author":"J Chan","year":"2020","unstructured":"Chan J, Jayamanne D, Wheeler H et al (2020) The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. Clin Transl Radiat Oncol 22:33\u201339. https:\/\/doi.org\/10.1016\/j.ctro.2020.03.005","journal-title":"Clin Transl Radiat Oncol"},{"key":"5635_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.radonc.2019.09.023","volume":"142","author":"GR Sarria","year":"2020","unstructured":"Sarria GR, Sperk E, Han X et al (2020) Intraoperative radiotherapy for glioblastoma: an international pooled analysis. Radiother Oncol 142:162\u2013167. https:\/\/doi.org\/10.1016\/j.radonc.2019.09.023","journal-title":"Radiother Oncol"},{"key":"5635_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1158\/1078-0432.CCR-20-0894","volume":"27","author":"P Montay-Gruel","year":"2021","unstructured":"Montay-Gruel P, Acharya MM, Gon\u00e7alves Jorge P et al (2021) Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice. Clin Cancer Res 27:775\u2013784. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0894","journal-title":"Clin Cancer Res"},{"key":"5635_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clineuro.2016.01.010","volume":"142","author":"N Montemurro","year":"2016","unstructured":"Montemurro N, Perrini P, Blanco MO, Vannozzi R (2016) Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin Neurol Neurosurg 142:60\u201364. https:\/\/doi.org\/10.1016\/j.clineuro.2016.01.010","journal-title":"Clin Neurol Neurosurg"},{"key":"5635_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-017-2731-2","volume":"137","author":"A Wann","year":"2018","unstructured":"Wann A, Tully PA, Barnes EH et al (2018) Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. J Neurooncol 137:409\u2013415. https:\/\/doi.org\/10.1007\/s11060-017-2731-2","journal-title":"J Neurooncol"},{"key":"5635_CR43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11060-016-2330-7","volume":"131","author":"P Perrini","year":"2017","unstructured":"Perrini P, Gambacciani C, Weiss A et al (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol 131:585\u2013591. https:\/\/doi.org\/10.1007\/s11060-016-2330-7","journal-title":"J Neurooncol"},{"key":"5635_CR44","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/fon.16.9","volume":"12","author":"AA Brandes","year":"2016","unstructured":"Brandes AA, Bartolotti M, Tosoni A et al (2016) Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol 12:1039\u20131044. https:\/\/doi.org\/10.2217\/fon.16.9","journal-title":"Future Oncol"},{"key":"5635_CR45","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/14796694.2024.2358743","volume":"20","author":"M Lecce","year":"2024","unstructured":"Lecce M, Rasile F, Tanzilli A et al (2024) Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life. Future Oncol 20:1565\u20131573. https:\/\/doi.org\/10.1080\/14796694.2024.2358743","journal-title":"Future Oncol"},{"key":"5635_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2176\/nmc.oa.2020-0308","volume":"61","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi S, Motegi H, Ishi Y et al (2021) Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis. Neurol Med Chir (Tokyo) 61:245\u2013252. https:\/\/doi.org\/10.2176\/nmc.oa.2020-0308","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5635_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11060-011-0744-9","volume":"107","author":"K-J Park","year":"2012","unstructured":"Park K-J, Kano H, Iyer A et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107:323\u2013333. https:\/\/doi.org\/10.1007\/s11060-011-0744-9","journal-title":"J Neurooncol"},{"key":"5635_CR48","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","volume":"82","author":"KC Cuneo","year":"2012","unstructured":"Cuneo KC, Vredenburgh JJ, Sampson JH et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018\u20132024. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.12.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5635_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.surneu.2006.11.042","volume":"68","author":"M Terasaki","year":"2007","unstructured":"Terasaki M, Ogo E, Fukushima S et al (2007) Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. Surg Neurol 68:250\u2013254. https:\/\/doi.org\/10.1016\/j.surneu.2006.11.042","journal-title":"Surg Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05635-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05635-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05635-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:17Z","timestamp":1785521297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05635-y"}},"subtitle":["FROST: multimodal treatment for GBM recurrence"],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5635"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05635-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients received an information sheet and a non-oposition consent form for their registration within the database. The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Institut de Canc\u00e9rologie Strasbourg Europe N\u00b0 IRB 2024-23 on September the 24th 2024. The Institut de Canc\u00e9rologie Strasbourg Europe (ICANS) is committed to adhering to the reference methodology MR-004 published by the CNIL.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}